Nanofiber Solutions
Jed Johnson has a diverse work experience in various industries. Jed started their career as a Research Fellow at The Ohio State University, where they worked on tissue engineering applications. After completing their Ph.D., they co-founded Nanofiber Solutions and served as the Chief Technology Officer. Jed then went on to co-found and serve as the CTO at Atreon Orthopedics, Phoenix Wound Matrix by RenovoDerm, and Matrix Food Technologies, Inc. Additionally, Jed has held positions in organizations such as Ohio Climbers Coalition and Solid Rock Climbers For Christ. Earlier in their career, they gained experience as a Product Engineer Intern at Exactech and as a Cylinders Engineer Intern at Worthington Industries.
Jed Johnson obtained their Bachelor of Science (BS) degree in Materials Science from The Ohio State University in 2009. Jed then continued their education at the same institution and received their Master of Science (MS) degree in Materials Science in 2010. Additionally, they completed their Doctor of Philosophy (PhD) degree in Materials Science from The Ohio State University in 2010 as well. In terms of additional certifications, Jed obtained "Grow to Greatness: Smart Growth for Private Businesses, Part I" and "Grow to Greatness: Smart Growth for Private Businesses, Part II" from Coursera in March 2013 and May 2013, respectively.
This person is not in any teams
This person is not in any offices
Nanofiber Solutions
1 followers
Nanofiber Solutions develops and markets electrospun nanofiber substrates for cell culture and drug development applications in standard multiwell plates or it can be scaled for larger configurations. Historically, general cell culture has been performed on flat, tissue culture polystyrene (TCPS) because it is cheap, optically clear, and many cellsgrow well on it. In reality, however, living organisms are made up of an extracellular matrix (ECM) that presents both aligned physical structure and mechanical support to the cells. Adherent cells are complex, self-sustaining units that require ECM anchorage to proliferate and undergo normal differential function. TCPS lacks this aligned three-dimensional (3-D) component and cells behave very differently on this flat, smooth substrate than they do in true biological settings. Not surprisingly, drugs developed using TCPS as an in vitro substrate experience a >99% failure rate in clinical studies.